These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33213078)

  • 21. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
    Mirabelli M; Chiefari E; Caroleo P; Vero R; Brunetti FS; Corigliano DM; Arcidiacono B; Foti DP; Puccio L; Brunetti A
    J Diabetes Res; 2019; 2019():3971060. PubMed ID: 31781664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
    Kanters S; Wilkinson L; Vrazic H; Sharma R; Lopes S; Popoff E; Druyts E
    BMJ Open; 2019 Jul; 9(7):e023458. PubMed ID: 31340953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular Filtration Rate.
    Chonko K; Russo-Alvarez G; Isaacs D; Wang L; Soric A
    Innov Pharm; 2023; 14(2):. PubMed ID: 38025173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review.
    Lin Y; Mok M; Harrison J; Battistella M; Farrell A; Leung M; Cheung C
    Transplant Rev (Orlando); 2023 Jan; 37(1):100729. PubMed ID: 36427372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Lu J; Tang L; Meng H; Zhao J; Liang Y
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of the combination or monotherapy with GLP-1 receptor agonists and SGLT-2 inhibitors in Type 2 diabetes mellitus: An update systematic review and meta-analysis.
    Tuersun A; Hou G; Cheng G
    Am J Med Sci; 2024 Jul; ():. PubMed ID: 38977245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Pan R; Zhang Y; Wang R; Xu Y; Ji H; Zhao Y
    PLoS One; 2022; 17(12):e0279889. PubMed ID: 36584211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
    Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
    Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers.
    Demir ME; Özler TE; Merhametsiz Ö; Sözener U; Uyar M; Ercan Z; Bardak Demir S; Sezer S; Türkmen Sarıyıldız G
    Int Urol Nephrol; 2023 Nov; 55(11):2989-2999. PubMed ID: 37289399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis.
    Oikonomaki D; Dounousi E; Duni A; Roumeliotis S; Liakopoulos V
    Diabetes Res Clin Pract; 2021 Feb; 172():108604. PubMed ID: 33338553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Davies MJ; Patsko E; Dhalwani NN; Kloecker DE; Ioannidou E; Gray LJ
    Diabetes Obes Metab; 2020 Jul; 22(7):1035-1046. PubMed ID: 32077218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for metformin: a systematic review and meta-analysis of randomized controlled trials.
    Li X; Zhang Q; Zhou X; Guo S; Jiang S; Zhang Y; Zhang R; Dong J; Liao L
    Aging (Albany NY); 2021 May; 13(9):12748-12765. PubMed ID: 33973870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comparative Study of efficacy and safety of different Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitors in the Management of Patients with Type II Diabetes Mellitus.
    Bhosle D; Indurkar S; Quadri U; Chandekar B
    J Assoc Physicians India; 2022 Jun; 70(6):11-12. PubMed ID: 35702841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 individuals.
    Huang CY; Lee JK
    Diabetes Obes Metab; 2020 Dec; 22(12):2348-2355. PubMed ID: 32744411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.
    Avgerinos I; Manolopoulos A; Michailidis T; Kitsios K; Liakos A; Karagiannis T; Dimitrakopoulos K; Matthews DR; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2021 Mar; 23(3):822-831. PubMed ID: 33300282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.